Targeson Inc is categorized under Commercial Biotechnical Research in San Diego, CA and active since 2010.
Targeson Inc was established in 2010, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact Jack Defranco at the company’s single location by writing to 3550 General Atomics Court, San Diego, California CA 92121 or by phoning (877) 290-4043. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Targeson Inc |
| Contact Person: | Jack Defranco |
| Address: | 3550 General Atomics Court, San Diego, California 92121 |
| Phone Number: | (877) 290-4043 |
| Website Address: | targeson.com |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2010 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541711 |
| Share This Business: |
Targeson Inc was started in 2010 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Jack Defranco for inquiries that concern Targeson Inc by calling the company number (877) 290-4043, as your correspondence is most welcome. Additionally, the physical location of the single location of Targeson Inc can be found at the coordinates 32.894266,-117.237629 as well as the street address 3550 General Atomics Court in San Diego, California 92121.
For its online presence, you may visit Targeson Inc’s website at targeson.com and engage with its social media outlets through on Twitter and on Facebook.